Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: A prospective, open-label, parallel-cohort, single-center study

2011 ◽  
Vol 63 (6) ◽  
pp. 1486-1496 ◽  
Author(s):  
Cem Gabay ◽  
Michael Bel ◽  
Christophe Combescure ◽  
Camillo Ribi ◽  
Sara Meier ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Pandemic Influenza ◽  
Antibody Responses ◽  
Single Center ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Open Label ◽  
Single Center Study ◽  
Disease Modifying ◽  
Center Study

scholarly journals Treatment with the Interleukin-17A-Blocking Antibody Secukinumab Does Not Interfere with the Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects: Results of an Open-Label, Parallel-Group, Randomized Single-Center Study

2012 ◽  
Vol 19 (10) ◽  
pp. 1597-1602 ◽  
Author(s):  
A. Chioato ◽  
E. Noseda ◽  
M. Stevens ◽  
N. Gaitatzis ◽  
A. Kleinschmidt ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Healthy Subjects ◽  
Antibody Responses ◽  
Control Group ◽  
Single Center ◽  
Open Label ◽  
Interleukin 17A ◽  
Parallel Group ◽  
Single Center Study ◽  
Center Study

ABSTRACTOur objective was to evaluate the efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to the anti-interleukin-17A (IL-17A) monoclonal antibody (MAb) secukinumab. We used an open-label, parallel-group, randomized single-center study of 50 healthy subjects. Subjects received a single 150-mg dose of secukinumab or no treatment, followed by vaccination with inactivated trivalent subunit influenza virus and conjugate group C meningococcal vaccine (Agrippal and Menjugate, respectively) 2 weeks later. Primary efficacy variables were responses of ≥4-fold increases in antibody titer (hemagglutination inhibition [HI; for influenza virus] and serum bactericidal assay [SBA; forNeisseria meningitides]) for meningococcus and influenza (at least two out of three serotypes), both at 4 weeks postvaccination. All subjects randomized to secukinumab (n= 25) or the control (n= 25) completed the study. Antibody responses to vaccinations measured at 4 weeks were comparable in both groups, with ≥4-fold increased responses following influenza virus vaccination of 20/25 (80%) for both groups and following meningococcal vaccination of 19/25 (76%) for the secukinumab group and 18/25 (72%) for the control group. Differences between groups were 0% (90% confidence intervals [CI], 19 and 19%) and 4% (90% CI, 16 and 24%) for influenza virus and meningococcal vaccines, respectively. Antibody responses were comparable between the 2 groups at different time points. Headache was the most frequently reported adverse effect. No deaths or serious adverse events were reported. Blockade of IL-17A by secukinumab does not appear to interfere with efficacy of influenza and meningococcal vaccinations, as assessed by the achievement of protective antibody levels. A protective (≥4-fold) immune response to both vaccinations at 4 weeks was achieved in 80 and 76% of subjects exposed to secukinumab and the control, respectively.

scholarly journals Evaluation of vinpocetine as a therapy in patients with sensorineural hearing loss: A phase II, open-label, single-center study

2021 ◽  
Vol 145 (4) ◽  
pp. 313-318
Author(s):  
Ileana Gutiérrez-Farfán ◽  
Celia Reyes-Legorreta ◽  
Mauricio Solís-Olguín ◽  
Efrén Alatorre-Miguel ◽  
Antonio Verduzco-Mendoza ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Phase Ii ◽  
Sensorineural Hearing ◽  
Single Center ◽  
Open Label ◽  
Single Center Study ◽  
Center Study

Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs—a single-center analysis of 2054 patients

2018 ◽  
Vol 37 (11) ◽  
pp. 2963-2970 ◽  
Author(s):  
Eva C. Schwaneck ◽  
Manuel Krone ◽  
Sonja Kreissl-Kemmer ◽  
Benedikt Weißbrich ◽  
Johannes Weiss ◽  
...  
Keyword(s):  
Rheumatic Diseases ◽  
Single Center ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Disease Modifying

AB0580 A Prospective Open-Label Single Center Study of Adalimumab in Behcet Arthritis

2016 ◽  
Vol 75 (Suppl 2) ◽  
pp. 1103.1-1103
Author(s):  
Y. Braun-Moscovici ◽  
Y. Tavor ◽  
D. Markovits ◽  
M. Naffaa ◽  
K. Toledano ◽  
...  
Keyword(s):  
Single Center ◽  
Open Label ◽  
Single Center Study ◽  
Center Study
Sign in / Sign up

Export Citation Format

Share Document